Frankfurt - Delayed Quote EUR

MedinCell S.A. (MEB.F)

15.04

-0.04

(-0.27%)

At close: June 13 at 3:29:02 PM GMT+2

Medincell to Present 2024-2025 Annual Results on June 17, 2025

MONTPELLIER, France, June 10, 2025--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange.

Business Wire 3 days ago

MDCLF
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025

MONTPELLIER, France, May 28, 2025--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell’s (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET (1:35 p.m. CEST).

Business Wire 16 days ago

MDCLF
Truist Securities Initiates Medincell’s Coverage with a "Buy" Recommendation

MONTPELLIER, France, May 28, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 16 days ago

MDCLF
3 European Growth Companies With Insider Ownership Expecting Up To 115% Earnings Growth

The European stock market recently experienced a downturn, with the pan-European STOXX Europe 600 Index ending lower amid trade tensions and economic uncertainty. In this environment, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the company's operations.

Simply Wall St. 18 days ago

MDCLF

LCTSF
European Value Stocks Including MedinCell That May Be Priced Below Intrinsic Estimates

As European markets experience a boost in sentiment following the de-escalation of U.S.-China trade tensions, major indices such as the STOXX Europe 600 have shown positive performance. In this context, identifying stocks that are potentially undervalued can provide investors with opportunities to capitalize on market conditions where intrinsic value may not yet be fully recognized by broader market participants.

Simply Wall St. 22 days ago

SOTDF

SOTDY

MDCLF
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025

MONTPELLIER, France, May 07, 2025--Regulatory News: Medincell’s partner Teva Pharmaceuticals shared today the following information:

Business Wire last month

MDCLF
European Growth Companies With High Insider Ownership In April 2025

As trade tensions between the U.S. and China show signs of easing, European markets have responded positively, with major indices like Germany's DAX and France's CAC 40 seeing notable gains. Against this backdrop of cautious optimism, investors might find appeal in growth companies with high insider ownership, as these stocks often demonstrate strong alignment between management interests and shareholder value—a particularly attractive trait in uncertain economic climates.

Simply Wall St. last month

MDCLF

SAEYY

SHPPF
3 European Stocks Estimated To Be Trading Below Fair Value By Up To 49.4%

As European markets show signs of recovery, with the pan-European STOXX Europe 600 Index climbing 3.93% amid positive sentiment from delayed tariffs and potential ECB rate cuts, investors are increasingly on the lookout for stocks that may be trading below their intrinsic value. In such an environment, identifying undervalued stocks can offer opportunities for those seeking to capitalize on market inefficiencies and potentially benefit from favorable economic conditions.

Simply Wall St. last month

CINT.ST

NORBT.OL

NORBTO.OL
Medincell and iM4TB Initiate Development of a Long-Acting Injectable Version of Macozinone, a Promising Investigational Tuberculosis Treatment

MONTPELLIER, France, April 22, 2025--Regulatory News: MedinCell (Paris:MEDCL) :

Business Wire last month

MDCLF
Medincell Increases the Amount Allocated to the Liquidity Contract with Rothschild Martin Maurel

MONTPELLIER, France, April 15, 2025--Regulatory News: In order to accompany the increase in the volumes of shares traded daily, Medincell (Paris:MEDCL) signed on April 11, 2025 an amendment to the Liquidity Agreement entered into with Rothschild Martin Maurel on September 10, 2024, in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, Commission Delegated Regulation (EU) 2016/908 of February 26, 2016, Articles L. 225-20

Business Wire last month

MDCLF
Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI

MONTPELLIER, France, March 31, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 2 months ago

MDCLF
European Growth Stocks With High Insider Ownership March 2025

In March 2025, the European markets have shown resilience, with the STOXX Europe 600 Index ending higher after two weeks of losses, driven by optimism around potential government spending despite ongoing concerns about U.S. tariffs. As central banks navigate a complex landscape of growth and inflation challenges, investors are increasingly focusing on companies with strong fundamentals and high insider ownership as indicators of confidence in long-term growth potential.

Simply Wall St. 2 months ago

MDCLF

RTOBF

LCTSF
European Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.5%

As European markets navigate a complex landscape marked by hopes of increased government spending and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to snap two weeks of losses with a modest gain. Against this backdrop, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking opportunities in an environment where central banks are balancing growth concerns and inflation risks.

Simply Wall St. 2 months ago

LCTSF

MDCLF

CINT.ST
Medincell Strengthens its Board of Directors to Support its Growth

MONTPELLIER, France, March 06, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 3 months ago

MDCLF
3 European Growth Companies With Up To 19% Insider Ownership

As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth potential. In this environment, stocks with high insider ownership can be particularly appealing, as they often indicate confidence in the company's future prospects from those closest to its operations.

Simply Wall St. 3 months ago

MDCLF

RTOBF

LCTSF
Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA

MONTPELLIER, France, February 26, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 3 months ago

MDCLF
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 25, 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA).

Business Wire 3 months ago

TEVA

TEVJF

MDCLF
Medincell Announces Successful c.€43 Million Global Offering

MONTPELLIER, France, February 19, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 3 months ago

MDCLF
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital

MONTPELLIER, France, February 18, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 3 months ago

MDCLF
Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

MONTPELLIER, France, February 10, 2025--Regulatory News: Medincell (Paris:MEDCL):

Business Wire 4 months ago

MDCLF

Performance Overview

Return	MEB.F	CAC 40 (^FCHI)
YTD	-12.25%	+4.12%
1-Year	+0.27%	-0.30%
3-Year	+189.23%	+27.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MedinCell S.A. (MEB.F)

Medincell to Present 2024-2025 Annual Results on June 17, 2025

Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025

Truist Securities Initiates Medincell’s Coverage with a "Buy" Recommendation

3 European Growth Companies With Insider Ownership Expecting Up To 115% Earnings Growth

European Value Stocks Including MedinCell That May Be Priced Below Intrinsic Estimates

UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025

European Growth Companies With High Insider Ownership In April 2025

3 European Stocks Estimated To Be Trading Below Fair Value By Up To 49.4%

Medincell and iM4TB Initiate Development of a Long-Acting Injectable Version of Macozinone, a Promising Investigational Tuberculosis Treatment

Medincell Increases the Amount Allocated to the Liquidity Contract with Rothschild Martin Maurel

Medincell’s Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI

European Growth Stocks With High Insider Ownership March 2025

European Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.5%

Medincell Strengthens its Board of Directors to Support its Growth

3 European Growth Companies With Up To 19% Insider Ownership

Medincell to Present at the TD Cowen 45th Annual Healthcare Conference, March 3-5, 2025, Boston, MA

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Medincell Announces Successful c.€43 Million Global Offering

Medincell Launches a Global Offering for Approximately 10% of Its Share Capital

Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

Performance Overview